Pharmaceutical Filtration Market: Recent Trends and Developments

 Growth in the pharmaceutical filtration market can be attributed to factors such as rapid growth in the R&D and manufacturing of biopharmaceuticals, growing adoption of single use filters, new product developments by key market players, growing filtration scrutiny by regulatory bodies, and advanced development in nano fiber technologies. Despite this, issues such as membrane fouling, and the large capital investment required to set up new production facilities are expected to hinder market growth.

The report Pharmaceutical Filtration Market is projected to reach USD 26.2 billion by 2028 from USD 13.5 billion in 2023, at a CAGR of 14.2% during the forecast period of 2023 to 2028.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847

KEY MARKET DYNAMICS: 

         

           1 DRIVERS

                   1.1 Growing biopharmaceutical industry

                   1.2 Rising R&D spending in pharmaceutical and biotechnology industries

                   1.3 Increasing adoption of single-use technologies

                   1.4 New product launches by leading market players

                   1.5 Increasing purity requirements in end-user segments

           2 RESTRAINTS

                   2.1 Membrane fouling issues

                   2.2 Requirement of high capital investments for new production facilities

           3 OPPORTUNITIES

                   3.1 Growth opportunities in emerging economies

                   3.2 Advances in nanofiber technology

           4 CHALLENGES

                   4.1 Increased cost and reduced speed and yield of filters

                   4.2 Survival of small players and new entrants

 

Market Segmentation: -

Based on products, the pharmaceutical filtration market is segmented into filters, systems, and other products. Filters segment accounted for the largest share of the pharmaceutical market, membrane filters are the key revenue contributors to this segment. Membrane filters are microporous plastic films with specific pore size ratings. These filters are used to separate contaminated particles from liquids. They are available in a variety of polymers, pore sizes, diameters, and surface types.

Based on technique, the pharmaceutical filtration market is segmented into microfiltration, ultrafiltration, nanofiltration, and other techniques. The other techniques segment includes reverse osmosis and ion exchange. The nanofiltration techniques accounted for the smallest market share of this market in 2022, and this can be primarily attributed to the limited retention for salts and univalent ions by nanofilters; nanofiltration membranes being comparatively more expensive than reverse osmosis membranes.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=209343847

Regional Analysis:-

Based on the region, the Pharmaceutical filtration market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the rapid technology development in nanofiber technologies, expanding manufacturing of generics, growing government budget for R&D, and growing biotechnology industries.

Recent Developments:

• In January 2023, Sartorius AG (Germany) and RoosterBio, Inc. (US) signed a collaboration deal to provide purification solutions and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius will provide its scalable filtration equipment, such as SartoflowSmart and Sartoflow Advanced, for the clarification, concentration, and formulation of exosomes.
• In June 2022, Donaldson Company Inc. (US) acquired Purilogics, LLC (US), an early-stage biotechnology company that manufactures membrane chromatography products. Through this acquisition, the company will have access to the purification tools for a wide range of biologics, including mRNA, plasmid DNA, viral particles, monoclonal antibodies, and proteins that Purilogics offers.

Top Key Players:

Key players in the drug discovery service Market include Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), 3M (US), Thermo Fisher Scientific Inc. (US).

Conclusion:

The pharmaceutical filtration market is undergoing rapid evolution, driven by technological advancements, regulatory imperatives, and industry shifts toward sustainability and efficiency. As drug formulations become more complex and personalized, filtration techniques must keep pace to ensure the safety and effectiveness of pharmaceutical products.

 

Unlocking Potential: How Industry 4.0 Transforms Medical Device Outsourced Manufacturing

 Innovation in Class III medical devices is on the rise, consequent to the growing development and production of complex products such as pacemakers and implantable medical devices. Medical device companies face challenges in manufacturing Class III devices in high volumes, given the complexity of the assembly and test processes. Furthermore, both the devices and processes must meet regulatory compliance for component traceability and verification, storage, and access. 

Industry 4.0 technologies—including cloud computing, machine-to-machine communication, and cyber-physical systems—enable advanced automation that helps overcome these production challenges. The increased connectivity and data-gathering capabilities of these technologies make it possible to build high-volume, regulation-compliant manufacturing processes with efficient inventory and production management.

The Medical Device Outsourced Manufacturing Market is projected to reach USD 56.2 billion by 2026 from USD 29.3 billion in 2021 and is expected to grow at a CAGR of 13.9% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=477468

Market Segmentation: -

Based on device type, the Asia Pacific market is broadly segmented into IVD devices, diagnostic imaging devices, cardiovascular devices, drug delivery devices, orthopedic devices, respiratory care devices, ophthalmology devices, surgical devices, diabetes care devices, dental devices, endoscopy devices, gynecology/urology devices, personal care devices, neurology devices, and other devices. In 2020, the IVD devices segment accounted for the largest share of the Asia Pacific market.

Based on the class of device, the medical device outsourced manufacturing market is segmented into Class I, Class II, and Class III medical devices. In 2020, the Class II medical devices segment accounted for the largest share of the Asia Pacific market.

Based on service, the Asia Pacific medical device outsourced manufacturing market is segmented into device development and manufacturing services, quality management services, packaging and assembly services and other services.

Based on process, the Asia Pacific market is broadly segmented into production, prototyping, pilot production, design for manufacturing, process evaluation, validation, project management, packaging, and assembly.

Regional Analysis:

The Asia Pacific medical device outsourced manufacturing market, by country, has been segmented into China, Japan, Malaysia & Singapore, India, Australia & New Zealand, South Korea, and the Rest of APAC. China is expected to witness fastest growth during the forecast period of 2021–2026. China's fastest growth is mainly due to the lower cost of raw materials and labor in the country than in developed countries.

Recent Developments:

• In November 2020, Nipro Corporation (Japan) acquired Venari Medical’s (Ireland)  exclusive sales rights for a vascular treatment device developed by Venari Medical in Japan and overseas
• In October 2020, Nemera (France) acquired Copernicus (Poland) to become a leading patient-centric drug device combination solutions company. This acquisition will bolster the company’s production capabilities and expand its product portfolio
• In September 2020, Nipro Corporation established its sales offices in Xi'an, Wuhan, Hefei, and Xiamen. The new offices will further strengthen the company’s sales and service network in China to provide more community-based, meticulous services and respond to the needs of the medical scene, thereby enhancing the presence of the “Nipro brand”
• In January 2020, Nipro Asia Pte Ltd. (Singapore) acquired JMI Marketing (Bangladesh) to secure a large market share in Bangladesh’s rapidly growing economy for disposable medical devices, including infusion sets, syringes, and IV catheters

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=477468

Top Key Players: -

The prominent players in this medical device outsourced manufacturing market are Flex, Ltd. (Singapore), Jabil, Inc. (US), TE Connectivity, Ltd. (Switzerland), Sanmina Corporation (US), Nipro Corporation (Japan), Celestica International (Canada), Plexus Corporation (US), Benchmark Electronics, Inc. (US), Integer Holdings Corporation (US), Gerresheimer Ag (Germany), West Pharmaceutical Services, Inc. (US), Nortech Systems, Inc. (US), Consort Medical PLC (UK), Kimball Electronics Inc. (US), and Teleflex Incorporated (US), Nordson Corporation (US), Tecomet, Inc. (US), SMC Ltd. (US), Nemera (France), and Tessy Plastics Corporation (US), among others.

These driving growth factors are expected to continue shaping the Medical Device Outsourced Manufacturing Market as the medical device industry evolves, demands cost-effective solutions, and seeks to maintain compliance with regulatory standards while fostering innovation and agility.

Metagenomic Sequencing Market worth $4.5 billion in 2028, growing at a CAGR of 17.5%

 The Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields.

The global metagenomic sequencing market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $4.5 billion in 2028, growing at a CAGR of 17.5% from 2023 to 2028.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=60408643

Key Driving growth factors:

1 DRIVERS

                   1.1 Continuous technological innovations in NGS platforms

                               1.1.1 Ion Torrent Genexus Dx Integrated Sequencer

                               1.1.2 iSeq 100 System

                               1.1.3 Ion GeneStudio S5

                   1.2 Initiatives and funding from government & private bodies for large-scale sequencing projects

                   1.3 Declining cost of genome sequencing

                                 

                   1.4 Significant applications of metagenomics in various fields

 

Market Segmentation:

Among the products & service, the metagenomic sequencing market is segmented reagents & consumables, instruments, sequencing services and analysis & data interpretation solutions. In 2023, the reagents and consumables segment accounted for the largest share of the metagenomic sequencing market by product & service.

Among the applications, the metagenomic sequencing market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications.

Regional Analysis.

Geographically, the metagenomic sequencing market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The metagenomic sequencing market was dominated by North America in 2022 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2028.

Recent Developments:

• In September 2022, Illumina, Inc. (US) launched the NovaSeq X series production-scale sequencers, which are capable of generating more than 20,000 whole genomes per year (which is 2.5 times the throughput of prior sequencers from Illumina).
• In September 2021, Thermo Fisher Scientific, Inc. (US) and AstraZeneca(UK) co-developed an NGS-based companion diagnostic. The collaboration was focused on commercializing NGS-based diagnostics in Russia.  

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=60408643

Top Key Players:

The market for metagenomic sequencing is consolidated, with key players strategizing to capture the market. Prominent players in the metagenomic sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) among others.

The Metagenomic Sequencing Market is a dynamic and rapidly evolving industry with significant implications for various sectors, including healthcare, agriculture, environmental science, and biotechnology. Advances in technology and increased awareness of the importance of microbiome research are expected to continue driving growth in this market.

 

Navigating the Growth: Laser Capture Microdissection Market Analysis for Business Leaders

 As per the recently published report by MarketsandMarkets™, The report "Laser Capture Microdissection Market by Product (Instruments, Consumables, Software, Services), System Type (Ultraviolet, Infrared, Immunofluorescence), Application (R&D (Molecular Biology, Cell Biology, Forensics), Diagnostics) - Global Forecast to 2029", is projected to reach USD 306 million by 2029 from USD 184 million in 2024, at a CAGR of 10.6% during the forecast period of 2024 to 2029.

 
Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140404059
 
Browse

• 139     Market Data Tables
• 40       Figures
• 193     Pages and in-depth TOC on " Laser Capture Microdissection Market - Global Forecast to 2029”

Some of the prominent key players are:

• Thermo Fisher Scientific Inc. (US),
• Danaher Corporation (US),
• Carl Zeiss AG (Germany),
• F. Hoffmann-La Roche AG (Switzerland),
• Standard BioTools (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Laser Capture Microdissection Market.

 

Market Segmentation: -

• By product, the laser capture microdissection market has been further categorized as instruments, consumables, software and services. The consumables segment held the largest share of the global laser capture microdissection market in 2023. This can be attributed to increasing adoption of LCM technology across various research fields, advancements in sample preparation techniques, and the rising demand for personalized medicine.
• Based on application, the global laser capture microdissection market has been segmented into research & development, diagnostics, and other applications. The research & development segment held the largest market share in 2023.
• The laser capture microdissection market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to large pharmaceutical & biopharmaceutical industry in the region, the rising R&D expenditure, stringent regulations, and the presence of major providers of laser capture microdissection products in the US and Canada.

Recent Developments of Laser Capture Microdissection Industry:

• In August 2023, Danaher Corporation (US) acquired Abcam plc (UK), a leading supplier of protein consumables. Abcam is to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process using Danaher’s technology.
• In March 2023, Crown Bioscience International (US), a JSR Life Sciences Company, acquired a 100.0% stake in Indivumed Services GmbH& Co. KG (Germany) to further accelerate drug discovery and create solutions to meet customer needs by bringing a variety of synergistic service platforms to Crown Bioscience's drug discovery and development services.

Get Free Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=140404059

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is driven by increasing demand of laser capture microdissection in cancer research, collaborations between academic institutions, research organizations, and industry players to develop innovative LCM technologies. Additionally, continuous advancements in laser technology, microscopy, and automation have led to improved precision, efficiency, and ease of use of LCM systems.

Charting Progress: Healthcare Interoperability Solutions Market Aims for $6.2 Billion by 2027

 Growth in Healthcare Interoperability Solutions Market is driven by the increasing demand for efficient and cost-effictive healthcare delivery,  government initiatives towards improving the healthcare interoperability. However, the lack of true interoperability among electric systems, financial burden and technical difficulties in building and operations are some factors restraining the growth of the healthcare interoperability solutions market to a certain extent during the forecast period. The base year considered for the study is 2021, while, the forecast period is 2022 to 2027.

The report Healthcare Interoperability Solutions Market is projected to reach USD 6.2 billion by 2027 from USD 3.4 billion in 2022, at a CAGR of 12.9% during the forecast period.

 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17705847

KEY MARKET DYNAMICS 

           1 DRIVERS

                   1.1 Increasing demand for efficient and cost-effective healthcare delivery

                   1.2 Government initiatives and regulations to enhance patient care and safety

                   1.3 Emergence of new medical technologies

                   1.4 Growing adoption of electronic health records

           2 RESTRAINTS

                   2.1 Lack of accurate interoperability solutions across healthcare supply chain

                   2.2 Lack of standards and protocols in IT businesses

                   2.3 Use of outdated legacy systems in hospitals and clinic chains

          3 OPPORTUNITIES

                   3.1 Growing markets for healthcare interoperability solutions in developing countries

                   3.2 Advancements in software technology for real-time data exchange

          4 CHALLENGES

                   4.1 Increasing complexity due to lack of consistent data

                   4.2 Shortage of skilled healthcare IT professionals

                   4.3 Patient data security and privacy concerns in healthcare industry

 

Market Segmentation:

·         On the basis of type: the services segment accounted for the largest share. The large share of this segment can be attributed to the advantages offered by the services such as installation, equipment updates or traditional licensing management are not required in case of services.

·         Based on end user: the healthcare providers segment is expected to register the highest CAGR during the forecast period. The growing geriatric population leading to the increasing hospital admissions is contributing to the growth of this segment.

 

Regional Analysis:

North America accounted for the largest share of the healthcare interoperability solutions market in 2021, followed by Europe and Asia Pacific. The rising demand for value-based healthcare, the need to reduce the increasing healthcare costs, and the implementation of favorable government initiatives & regulations in the region are the key factors responsible for the large share of North America in the healthcare interoperability solutions market.

Recent Developments

·         In November 2022, Nextge Healthcare (US) acquired TSI Healthcare (US) to expand its presence in key specialties, including rheumatology, pulmonology, and cardiology.

·         In October 2022, Lyniate (US) partnered with CyncHealth (US) to help healthcare providers and health networks, payers, and public health departments power more meaningful data exchange.

·         In September 2022, Lyniate (US) partnered with BrightInsight (US) to improve Information Exchange for Regulated Digital Health Solutions Built on the BrightInsight Platform.

·         In July 2022, Intersystem Corporation (US) partnered with Bedfordshire Hospitals NHS Foundation Trust to develop a new shared health and care record, which is being rolled out across Bedfordshire and Luton.

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=17705847

Top Key Players: -

Some of the prominent players in this market are Cerner Corporation (US), Epic Systems Corporation (US), Infor, Inc. (US), Koninklijke Philips NV (Netherlands), InterSystems Corporation (US), Orion Health Group Limited (New Zealand), IBM Watson Health (US), Lyniate (US), Change Healthcare (US), NextGen Healthcare, Inc. (US), and Medical Information Technology, Inc. (US), iNTERFACEWARE (Canada), OSP Labs (US), ViSolve, Inc. (US), Jitterbit (US), Virtusa Corp. (US), and Summit Healthcare Services, Inc. (US).

Conclusion: -

In conclusion, the Healthcare Interoperability Solutions Market is poised for significant growth as healthcare organizations strive to improve patient outcomes through seamless data exchange and better care coordination. With advances in technology and increasing demand for interoperable systems, healthcare providers can expect to see increased efficiency, accuracy, and quality of care. The benefits of healthcare interoperability are far-reaching and can impact not only individual patient outcomes, but also the overall performance and sustainability of the healthcare system. The future of healthcare is centered on seamless integration and interoperability, and the Healthcare Interoperability Solutions Market is at the forefront of this revolution.

Progressive Projections: Organs-on-Chips Market on a Steady Climb

 As per the recently published report by MarketsandMarkets™, The report "Organ-On-Chip Market by Organ Type (Liver, Kidney, Intestine, Lung, Heart), Products (Instruments, Consumable, Software), Services (Standard, Custom), Model Type, Application (Toxicology, Drug Discovery, Stem Cell), Purpose - Global Forecast to 2029", is expected reach USD 631,073 thousand by 2029 from USD 123,285 thousand in 2024, at a CAGR of 38.6% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291
 
Browse

• 396     Market Data Tables
• 38       Figures
• 353     Pages and in-depth TOC on " Organ-On-Chip Market - Global Forecast to 2029”

Some of the prominent key players are:

• MIMETAS B.V. (Netherlands),
• TissUse GmBH (Germany),
• Netri (France),
• Emulate, Inc. (US),
• CN Bio Innovations Ltd (UK),
• Insphero AG (Switzerland),
• SynVivo, Inc. (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Organ-On-Chip Market.

Market Segmentation: -

• Among the model type subsegments, the market is segmented organ-based model and disease-based models. In 2023, the disease-based model segment accounted for the highest growth rate in the organ-on-chip market by model type. The high growth of this segment can be attributed to the growing adoption of disease based models for progressing studies associated with several conditions along with an application of these models in personalized medicine development.
• Among the organ type subsegment, the organ-on-chip market is segmented into liver, kidney, lung, heart, intestine and other organs. In 2023, liver-on-chip segment accounted for the fastest-growing market of the organ type segment of organ-on-chip market. The high growth of this market segment can be attributed to the growing focus on animal-free drug discovery and development methods and increasing preclinical research to evaluate drug hepatotoxicity
• The European market is the second-largest organ-on-chip market globally, mainly due to factors such as advancements in biofabrication technology and use of artificial intelligence in drug discovery and testing. The increased collaboration and partnership between private companies and government institutes along with increased awareness of the organ-on-chip technology are other important factors responsible for the size of the market.

Recent Developments of Organ-on-Chip Industry:

• In September 2023, CN Bio Innovations Ltd (UK) and LifeNet Health LifeSciences (US) partnered to provide validated human cells for CN Bio's Organ-on-a-Chip systems.  
• In June 2023 TissUse GmbH (Germany) and PMI (US) entered a collaborative agreement to leverage PMI's InHALES technology along with TissUse's Multi-Organ-Chip (MOC) platform. 

Growth in the organ-on-chip market can mainly be attributed to the increasing government initiatives to reduce drug testing on animal models. Additionally, factors such as advancements in biofabrication technologies and greater acceptance of organ-on-chip technology by pharma and biotechnology companies also contributes to the growth of this market. However, technical complexities of the organ-on-chip models along with low throughput of current organ-on-chip technology pose challenge for the market growth to a certain extent.